Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

Flaviviruses cause a significant amount of mortality and morbidity, especially in regions where they are endemic. A recent example is the outbreak of Zika virus throughout the world. Development of antiviral drugs against different viral targets is as important as the development of vaccines. During...

Full description

Saved in:
Bibliographic Details
Published in:Pathogens (Basel) 2022-02, Vol.11 (3), p.293
Main Authors: Samrat, Subodh K, Xu, Jimin, Li, Zhong, Zhou, Jia, Li, Hongmin
Format: Article
Language:English
Subjects:
Amino acids
Antiviral agents
Arthropods
Competition
Dengue fever
dengue virus
Drug development
Drug resistance
Encephalitis
Enzymes
Epidemics
FDA approval
Flavivirus
Genomes
Infections
inhibitors
Morbidity
NS2B-NS3
Protease
Proteinase
Proteins
Public health
Review
Vaccines
Vector-borne diseases
Viruses
West Nile virus
Zika virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Flaviviruses cause a significant amount of mortality and morbidity, especially in regions where they are endemic. A recent example is the outbreak of Zika virus throughout the world. Development of antiviral drugs against different viral targets is as important as the development of vaccines. During viral replication, a single polyprotein precursor (PP) is produced and further cleaved into individual proteins by a viral NS2B-NS3 protease complex together with host proteases. Flavivirus protease is one of the most attractive targets for development of therapeutic antivirals because it is essential for viral PP processing, leading to active viral proteins. In this review, we have summarized recent development in drug discovery targeting the NS2B-NS3 protease of flaviviruses, especially Zika, dengue, and West Nile viruses.
ISSN:2076-0817
2076-0817
DOI:10.3390/pathogens11030293